A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have a diagnosis of type 2 diabetes
Participants must have confirmed cardiovascular disease
Participants must have HbA1c 7.0% to 10.5%
Participants must have a body mass index (BMI) 25 kilograms per meter squared (kg/m²)
Participants Must Not:
Participants must not have had a major cardiovascular event within the last 60 days
Participants must not have type 1 diabetes mellitus
Participants must not have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
Participants must not have a history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
Participants must not be currently planning a coronary, carotid, or peripheral artery revascularization
Participants must not have a history of pancreatitis
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo